Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward

Overview

Journal Am J Transplant

Publisher Elsevier

Specialty General Surgery

Date 2016 Jan 6

PMID 26730885

Citations 26

Authors

M D Stegall

R E Morris

R R Alloway

R B Mannon

Affiliations

Soon will be listed here.

Abstract

The development of new immunosuppressive drugs has slowed markedly over the past several years, and the outlook that improved therapy will be available to the next generation of transplant recipients is bleak. In this viewpoint, the authors outline some of important barriers to new drug development and suggest specific steps that the transplant community can take to overcome them.

Citing Articles

New Immunosuppressants in Pediatric Kidney Transplantation: What's in the Pipeline for Kids?.

Tonshoff B, Patry C, Fichtner A, Hocker B, Bohmig G Pediatr Transplant. 2024; 29(1):e70008.

PMID: 39711054 PMC: 11664202. DOI: 10.1111/petr.70008.

Heart Transplant Rejection: From the Endomyocardial Biopsy to Gene Expression Profiling.

Farcas A, Stoica M, Maier I, Maier A, Sin A Biomedicines. 2024; 12(8).

PMID: 39200392 PMC: 11351478. DOI: 10.3390/biomedicines12081926.

Poised for Innovation: Considerations for End Points for New Drug Development in Kidney Transplantation.

Mannon R, Vincenti F J Am Soc Nephrol. 2024; 35(11):1603-1606.

PMID: 39102302 PMC: 11543003. DOI: 10.1681/ASN.0000000000000475.

Predicting long-term outcomes of kidney transplantation in the era of artificial intelligence.

Badrouchi S, Bacha M, Ahmed A, Ben Abdallah T, Abderrahim E Sci Rep. 2023; 13(1):21273.

PMID: 38042904 PMC: 10693633. DOI: 10.1038/s41598-023-48645-w.

Qualifying a Novel Clinical Trial Endpoint (iBOX) Predictive of Long-Term Kidney Transplant Outcomes.

Klein A, Loupy A, Stegall M, Helantera I, Kosinski L, Frey E Transpl Int. 2023; 36:11951.

PMID: 37822449 PMC: 10563802. DOI: 10.3389/ti.2023.11951.